Inflammation-Responsive Nanomaterials for Controlled Drug Release in Obesity-Related Chronic Inflammatory States

Muhindo Edgar

Department of Pharmacy Kampala International University Uganda

Email: edgar.muhindo@studwc.kiu.ac.ug

                                                             ABSTRACT
Obesity is characterized by chronic low-grade inflammation that plays a central role in the development of insulin resistance, type 2 diabetes, cardiovascular disease, and other components of metabolic syndrome. This inflammatory milieu is driven largely by dysfunctional white adipose tissue, immune cell infiltration, and sustained production of pro-inflammatory mediators. Conventional pharmacological interventions often fail to adequately target inflamed tissues and are associated with systemic side effects, reduced efficacy, and poor patient adherence. In this context, inflammation-responsive nanomaterials have emerged as a promising strategy for controlled, site-specific drug delivery in obesity-related chronic inflammatory states. These smart nanomaterials are engineered to respond to inflammatory cues such as acidic pH, elevated reactive oxygen species, proteolytic enzymes, and inflammatory cytokines, enabling precise and on-demand drug release at diseased sites. This review provides a comprehensive overview of the pathophysiological basis of obesity associated inflammation, principles of inflammation-responsive nanomaterial design, and key nanotechnological platforms developed for controlled drug release. We discuss current preclinical evidence supporting their therapeutic potential, address major translational challenges, and highlight future perspectives for integrating inflammation-responsive nanomedicine into metabolic disease management. Harnessing inflammation triggered drug delivery systems may represent a paradigm shift toward safer, more effective, and personalized therapies for obesity-related chronic inflammatory disorders.

Keywords: Inflammation-responsive nanomaterials; Obesity; Chronic inflammation; Controlled drug release; Metabolic syndrome.

CITE AS: Muhindo Edgar (2026). Inflammation-Responsive Nanomaterials for Controlled Drug Release in Obesity-Related Chronic Inflammatory States. NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES, 7(2):16-22.
https://doi.org/10.59298/NIJSES/2026/72.1622